Status:
COMPLETED
Eliminating Hepatitis C Virus
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Conditions:
Hepatitis C
HIV
Eligibility:
All Genders
18+ years
Brief Summary
Initially, HCV Informatics (C-IT) will be used to filter the EMR data of the one million people who receive care at Mount Sinai and identify candidates for HCV testing (baby boomers, patients with HIV...
Eligibility Criteria
Inclusion
- Inclusion criteria for HCV treatment in patients with HIV/HCV co-infection
- 18 years of age or older
- HCV RNA positive
- Any HCV genotype
- Documented infection with HIV, with the following additional criteria: - Patients on HAART should be on a stable regimen for 4 weeks, with a CD4 count \> 100, and an HIV viral load \< 50 prior to initiation of HCV therapy Patients not on HAART should have a CD4 count \> 350
- Expected life expectancy sufficient to receive a benefit from HCV cure
- No conditions that are contraindications for the use of HCV medications
- Inclusion criteria for HCV treatment in patients with type 2 diabetes
- 18 years of age or older
- HCV RNA positive
- Any HCV genotype
- Documented diagnosis of type 2 diabetes, confirmed by medical record review by the study endocrinologist, Dr. Sherley Abraham
- Expected life expectancy sufficient to receive a benefit from HCV cure
Exclusion
- No conditions that are contraindications for the use of HCV medications
Key Trial Info
Start Date :
January 23 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT03401697
Start Date
January 23 2018
End Date
March 1 2021
Last Update
March 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029